The Biden administration's proposal to make popular weight-loss drugs like Wegovy and Zepbound available through Medicare and Medicaid reflects a significant shift in public health policy, aiming to combat obesity among millions of Americans. However, the future of this initiative remains uncertain, especially with Trump’s incoming administration, which may have differing views on the drugs' efficacy and necessity.
Weight-loss drugs such as Ozempic and Wegovy can promote significant weight reduction, with clinical trials showing average losses of 15% to 22%. Yet, the accessibility of these treatments has been limited due to regulatory barriers, pushing many to face prohibitive out-of-pocket costs. If approved, the Medicare and Medicaid coverage could open doors for many who are currently struggling with obesity.
Collection
[
|
...
]